Vectura Group plc flutiform® k-haler®now available in Europe
10 September 2018 - 6:57PM
RNS Non-Regulatory
TIDMVEC
Vectura Group plc
10 September 2018
flutiform(R) k-haler(R)now available in Europe
New breath-triggered ICS/LABA combination aerosol inhaler
launches in UK
Chippenham, UK - 10 September 2018: The Mundipharma global
network of independent associated companies has announced that
flutiform(R) k-haler(R) is now available in Europe for adults and
adolescents (aged 12 years and older) with asthma where the use of
a combination product (inhaled corticosteroid, ICS, and long-acting
<BETA>(2) -agonist, LABA) is appropriate. The new inhaler has
initially been launched in the UK. Further launches are anticipated
across European countries in the coming months.
Geraldine Venthoye, Executive Vice President, Pharmaceutical and
Device Development, Vectura, commented: "Uncontrolled asthma is
commonly associated with incorrect inhaler technique, coupled with
poor adherence to therapy. The launch of this enhanced device,
designed to help patients take their medicine and reduce critical
errors, is a natural extension of the flutiform(R) franchise.
Europe remains a competitive and challenging ICS-LABA market and
the launch of the flutiform(R) k-haler(R) will help support
continued growth."
The existing flutiform(R) pMDI (pressurised metered dose
inhaler) combination treatment was developed by Vectura and
launched in 2012 in Europe and ROW by Mundipharma and in 2013 in
Japan by Kyorin. Vectura earns revenue from product supply and
royalties from in-market net sales. In 2017 flutiform(R) generated
total product supply and royalty revenue for Vectura of GBP68.5
million.
Ends
For more information, please contact:
Vectura Group plc
David Ginivan - VP Corporate Communications +44 (0)7471 352 720
Julia Wilson - Director Investor Relations +44 (0)7818 430877
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Jessica Hodgson / David Daley
About flutiform(R) k-haler(R)
flutiform(R) k-haler(R) is a novel asthma treatment for adults
and adolescents (aged 12 years and older) where the use of a
combination product (inhaled corticosteroid [ICS] and long-acting
<BETA>2-agonist [LABA]) is appropriate. It is a unique
breath-triggered inhaler utilising a patented 'kinked' valve - the
k-valve(TM) . The device is activated with a low inspiratory force,
and is designed to help patients who find it difficult to
co-ordinate actuation and inhalation with a standard pMDI
device.
About asthma
Asthma is a chronic inflammatory disorder of the airways which
leads to recurrent episodes of wheezing, breathlessness, chest
tightness and coughing. Patients with poorly managed asthma are at
an increased risk of exacerbations, hospitalisation and death.
Poorly managed asthma can also have a huge impact on a person's
quality of life and day-to-day activities.
About Vectura
Vectura is an industry-leading inhaled product formulation,
device design and development business offering a uniquely
integrated inhaled drug delivery platform. We develop inhalation
products to help patients suffering from airways diseases.
Vectura has eight key inhaled, two non-inhaled and ten oral
products marketed by partners with growing global royalty streams,
and a diverse partnered portfolio of drugs in clinical development.
Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin,
Baxter, GSK, UCB, Ablynx, Bayer, Chiesi, Almirall, Janssen, Dynavax
and Tianjin KingYork.
Vectura's strategy is to fully leverage its differentiated
technology and skills, maximising value by enhancing the delivery
and performance of inhaled products and through the development of
high-quality generic alternatives to branded therapies.
For further information, please visit Vectura's website at
www.vectura.com.
(R) FLUTIFORM is a registered trade mark of Jagotec AG and is
used under licence
(R) K-HALER is a registered trade mark of Mundipharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEANNNEEKPEFF
(END) Dow Jones Newswires
September 10, 2018 04:57 ET (08:57 GMT)
Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2024 to May 2024
Vectura (LSE:VEC)
Historical Stock Chart
From May 2023 to May 2024